GlassScriptPhysician profile
Naseeruddin A Khan
NPI 1912954496
$1,856.54
in general payments reported to CMS, 2019-2025
20 companies · $87.56 in 2025
The $87.56 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $133 · 2021: $193 · 2022: $890 · 2023: $219 · 2024: $335 · 2025: $87.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $640 · Education: $1.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $640.03 |
| Education | $1.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $356.91 | 2022-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $224.03 | 2023-2024 | Lupkynis |
| Vifor Pharma, INC. | $191.46 | 2021-2024 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $148.68 | 2021-2023 | |
| Amgen INC. | $143.12 | 2019-2024 | Tavneos |
| Astrazeneca Pharmaceuticals LP | $140.63 | 2021-2024 | Lokelma, Farxiga |
| Baxter Healthcare | $117.79 | 2022 | |
| Calliditas Therapeutics US INC. | $116.14 | 2024 | |
| Opko Pharmaceuticals, LLC | $108.26 | 2021-2022 | |
| Novo Nordisk INC | $93.22 | 2022-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $37.25 | 2025 | |
| Alexion Pharmaceuticals, INC. | $28.91 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $28.76 | 2022 | |
| Glaxosmithkline, LLC. | $25.77 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $21.70 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $21.60 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $20.02 | 2023 | Uzedy |
| Cranial Technologies, INC | $19.76 | 2025 | Doc Band |
| Mallinckrodt Enterprises LLC | $11.22 | 2019 | |
| Travere Therapeutics, INC. | $1.31 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naseeruddin Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.